Are you Dr. Lanasa?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 76 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2100 Erwin Rd
Durham, NC 27710Phone+1 919-684-8964Fax+1 919-684-5325- Is this information wrong?
Summary
- Dr. Mark Lanasa, MD is an oncologist in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina and Maryland. He is affiliated with University of North Carolina Hospitals and is an Assistant Professor at Duke University School of Medicine.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008- Duke University HospitalResidency, Internal Medicine, 2002 - 2005
University of Pittsburgh School of MedicineClass of 2002
Certifications & Licensure
MD State Medical License 2017 - 2019
NC State Medical License 2005 - 2014
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia Start of enrollment: 2007 May 10
- Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM Start of enrollment: 2008 Jun 19
- Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsNatural history of monoclonal B-cell lymphocytosis among relatives in CLL families.Susan L. Slager, Mark C. Lanasa, Gerald E. Marti, Sara J. Achenbach, Nicola J. Camp, Fatima Abbasi, Neil E. Kay, Celine M. Vachon, James R. Cerhan, James B. Johnston, ...> ;Blood. 2021 Apr 15
- 54 citationsPhase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200Daruka Mahadevan, Mark C. Lanasa, Charles M. Farber, Manjari Pandey, Maria Whelden, Susan J. Faas, Terrie L Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, Xiaopin...> ;Journal for Immunotherapy of Cancer. 2019 Aug 23
- 60 citationsActionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.Alexandra Schrader, Giuliano Crispatzu, Sebastian Oberbeck, Petra Mayer, S. Pützer, J. von Jan, Elena Vasyutina, Kathrin Warner, Nicole Weit, Natali Pflug, Till Braun,...> ;Nature Communications. 2018 Feb 15
- Join now to see all
Press Mentions
BeiGene and Novartis's Tislelizumab Makes Late-Stage Progress Against Liver CancerAugust 9th, 2022- BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell CarcinomaJune 30th, 2022
- China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal CancerJune 10th, 2022
- Join now to see all
Hospital Affiliations
University of North Carolina HospitalsChapel Hill, North Carolina
